Key result
Allisartan reduces nocturnal systolic blood pressure by ~13 mmHg.
Why the study?
Nocturnal blood pressure is an important predictor of cardiovascular events and death in hypertensive patients, but the comparative efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction required evaluation.
Do angiotensin receptor blockers (ARBs) reduce nocturnal blood pressure in patients with mild to moderate hypertension?
Meta-Analysis (n=13,314)
Do angiotensin receptor blockers (ARBs) reduce nocturnal blood pressure in patients with mild to moderate hypertension?
Mean Difference: -13.04 (95% CI -18.41–-7.68)
Long-acting ARBs, particularly allisartan, olmesartan, and telmisartan, effectively reduce nocturnal systolic blood pressure, with allisartan uniquely reducing nighttime BP more than daytime BP and improving the dipping pattern.
Supports allisartan preference among ARBs for nocturnal hypertension; extends meta-analytic evidence that long-acting agents improve dipping patterns.
BACKGROUND: Nocturnal blood pressure (BP) is correlated with an increased risk of cardiovascular events and is an important predictor of cardiovascular death in hypertensive patients. OBJECTIVE: Nocturnal BP control is of great importance for cardiovascular risk reduction. This systematic review and meta-analysis aimed to explore the efficacy of angiotensin receptor blockers (ARBs) for nocturnal BP reduction in patients with mild to moderate hypertension. METHODS: PICOS design structure was used to formulate the data extraction. All statistical calculations and analyses were performed with R. RESULTS: Seventy-seven studies with 13,314 participants were included. The overall analysis indicated that nocturnal BP drop varied considerably among different ARBs. Allisartan (13.04 [95% CI (-18.41, -7.68)] mmHg), olmesartan (11.67 [95% CI (-14.12, -9.21)] mmHg), telmisartan (11.11 [95% CI (-12.12, -10.11)] mmHg) were associated with greater reduction in nocturnal systolic BP. In the aspect of the nocturnal-diurnal BP drop ratio, only allisartan was greater than 1. While, the variation tendency of last 4-6 h ambulatory BP was basically consistent with nocturnal BP. Additionally, allisartan showed improvement effect in the proportion of patients with dipping BP pattern. CONCLUSIONS: This study demonstrates that for patients with mild to moderate hypertension, allisartan, olmesartan and telmisartan have more advantages in nocturnal BP reduction among the ARBs, while allisartan can reduce nighttime BP more than daytime BP and improve the dipping pattern.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) conducted a meta-analysis in Mild to moderate hypertension (n=13,314). Angiotensin receptor blockers (Allisartan) vs. Baseline was evaluated on Nocturnal ambulatory systolic blood pressure drop (MD -13.04 mmHg, 95% CI -18.41, -7.68). Among angiotensin receptor blockers, allisartan demonstrated significant nocturnal blood pressure reduction, reducing nocturnal systolic blood pressure by 13.04 mmHg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: